Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

BÇü °£¿° µ¿¹Ý ¿ø¹ß¼º °£¾Ï ȯÀÚ¿¡¼­ÀÇ CYP2D6¿Í NAT2 ´ÙÇü Çö»ó¿¡ °üÇÑ ¿¬±¸ CYP2D6 and NAT2 Polymorphism in HBV Associated in Hepatocellular CarcinomaPatients in Korea

´ëÇÑ¿Ü°úÇÐȸÁö 2002³â 62±Ç 2È£ p.150 ~ 156
½Åµ¿ÀÏ, ÀÌ°æ±Ù, À̱¤¼ö, Á¶À²Èñ,
¼Ò¼Ó »ó¼¼Á¤º¸
½Åµ¿ÀÏ ( Shin Dong-Ill ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

ÀÌ°æ±Ù ( Lee Kyeong-Geun ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
À̱¤¼ö ( Lee Kwong-Soo ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Á¶À²Èñ ( Cho Youl-Hee ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ À¯ÀüÇб³½Ç

Abstract


Purpose: CYP2D6 and N-acetyltransferase (NAT2) are polymorphic
enzymes which are expressed in the hepatocyte in a genotype-determined
manner. They are known to be involved in the inactivation and activation of
various mutagens and carcinogens, respectively. The activities of the two
enzyme systems are associated with the genetic susceptibility of many human
cancers. Methods: This study was performed to determine the genotype
frequencies of the two enzyme systems in primary hepatocellular carcinoma
patients and healthy controls. One hundred healthy controls and 55 liver
cancer patients were analyzed by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP). Results: In the healthy
controls, the CYP2D6 wild type allele frequency was 0.985 and the CYP2D6*4
frequency was 0.015. No CYP2D6 poor-metabolizer was detected. No significant
differences were found in the hepatocellular carcinoma patients group. Among
the controls, the frequencies of F, S1, S2 and S3 alleles of the NAT2 system
were 0.725, 0.01, 0.14 and 0.125, respectively. The genotype frequencies
were found to be 0.91 for the rapid acetylator and 0.09 for the slow
acetylator. No significant differences were found in the hepatocellular
carcinoma group. Conclusion: The distribution of CYP2D6 and NAT2
polymorphism is very unique in the Korean population, as characterized by
the extremely low frequency of CYP2D6 poor-metabolizer and NAT2 slow
acetylator. CYP2D6 and NAT2 polymorphisms did not seem to play an important
role in the hepatic carcinogenesis in the Korean population.

Å°¿öµå

¿ø¹ß¼º °£¾Ï; BÇü °£¿°; CYP2D6¿Í NAT2 ´ÙÇüÇö»ó; Hepatocellular carcinoma; Hepatitis B; CYP2D6 and NAT2 polymorphism;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS